• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    12/23/22 4:31:50 PM ET
    $ISO
    $LPCN
    $MSPR
    $NBSE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ISO alert in real time by email

    Gainers

    • NexImmune (NASDAQ:NEXI) shares increased by 15.4% to $0.28 during Friday's after-market session. The market value of their outstanding shares is at $7.3 million.
    • Lipocine (NASDAQ:LPCN) stock rose 9.72% to $0.44. The market value of their outstanding shares is at $38.9 million.
    • Tenax Therapeutics (NASDAQ:TENX) shares increased by 8.69% to $0.12. The market value of their outstanding shares is at $5.5 million.
    • Precipio (NASDAQ:PRPO) shares moved upwards by 8.59% to $0.6. The market value of their outstanding shares is at $13.6 million.
    • Exicure (NASDAQ:XCUR) shares increased by 8.59% to $1.39. Exicure's trading volume hit 375.9K shares by close, accounting for 192.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.9 million.
    • Omeros (NASDAQ:OMER) shares moved upwards by 6.69% to $2.71. The company's market cap stands at $169.9 million.

    Losers

    • NeuBase Therapeutics (NASDAQ:NBSE) shares decreased by 10.3% to $0.2 during Friday's after-market session. The company's market cap stands at $6.6 million. As per the news, the Q4 earnings report came out 2 days ago.
    • MSP Recovery (NASDAQ:MSPR) stock decreased by 8.91% to $1.33. The company's market cap stands at $98.2 million.
    • Venus Concept (NASDAQ:VERO) shares decreased by 6.34% to $0.28. Trading volume for this security closed at 166.6K, accounting for 9.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.4 million.
    • IsoPlexis (NASDAQ:ISO) shares declined by 6.14% to $1.53. Today's trading volume for this security ended up closing at 185.5K shares, which is 23.4 percent of its average volume over the last 100 days. The company's market cap stands at $60.5 million.
    • Palisade Bio (NASDAQ:PALI) stock decreased by 5.76% to $1.8. The company's market cap stands at $2.5 million.
    • Provention Bio (NASDAQ:PRVB) shares declined by 4.99% to $9.14. The company's market cap stands at $796.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ISO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISO
    $LPCN
    $MSPR
    $NBSE

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Omeros Corporation
    $OMER
    6/10/2025$9.00Buy
    H.C. Wainwright
    Omeros Corporation
    $OMER
    12/23/2024$36.00Buy
    D. Boral Capital
    Omeros Corporation
    $OMER
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    2/20/26 9:40:28 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TZIELD issued to PROVENTION BIO INC

    Submission status for PROVENTION BIO INC's drug TZIELD (ORIG-1) with active ingredient TEPLIZUMAB-MZWV has changed to 'Approval' on 11/17/2022. Application Category: BLA, Application Number: 761183, Application Classification:

    11/21/22 12:03:06 AM ET
    $PRVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/29/22 4:34:43 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for TESTOSTERONE UNDECANOATE

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    12/20/20 4:30:41 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Announces Q4 and year-end 2025 Shareholder Update Call

    NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be

    3/12/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou

    3/10/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

    SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence. The progress we've made, especially with our postpartum depression therapeutic, LPCN 1154, demonstrates the strength of our science and our team's c

    3/10/26 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    SEC Filings

    View All

    SEC Form 10-K filed by Tenax Therapeutics Inc.

    10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:48:55 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:32:44 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lipocine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Lipocine Inc. (0001535955) (Filer)

    3/10/26 6:13:03 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Financials

    Live finance-specific insights

    View All

    Precipio Announces Q4 and year-end 2025 Shareholder Update Call

    NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be

    3/12/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou

    3/10/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

    SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence. The progress we've made, especially with our postpartum depression therapeutic, LPCN 1154, demonstrates the strength of our science and our team's c

    3/10/26 8:00:00 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ISO
    $LPCN
    $MSPR
    $NBSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care